申请人:Pfizer Limited
公开号:EP0169012A1
公开(公告)日:1986-01-22
Compounds of the formula:
and pharmaceutically acceptable acid addition salts thereof, wherein R1 is at the 3 or 4 position and is phenyl or phenyl substituted by halo Ci-C4 alkoxy, or CZ-C5 alkoxycarbonyl; R2 is at the 2 or 7 position and is a group of the formula X(CH2)nNR3R4 wherein X is -CH = CH- or -(CH2)2-; n is 1, 2, 3 or 4; and either R3 and R4 are each independently H or C1-C4 alkyl, or R3 and R4 together with the nitrogen atom to which they are attached form a I-pyrrolidinyl or piperidino group; Y is H, C1-C4 alkyl, C1-C4 alkoxy or a CZ-C5 alkoxycarbonyl group at the 4, 5, 6 or 7 position; and wherein when R2 is at the 2-position, R1 is at the 3- or 4-position, or alternatively when R2 is at the 7-position, R1 is at the 3-position; are useful for the treatment of diarrhoea in humans and animals.
式中的化合物:
及其药学上可接受的酸加成盐,其中 R1 位于 3 或 4 位,是苯基或被卤代 Ci-C4 烷氧基或 CZ-C5 烷氧基羰基取代的苯基;R2 位于 2 或 7 位,是式 X(CH2)nNR3R4 的基团,其中 X 是 -CH = CH- 或 -(CH2)2-;n 是 1、2、3 或 4;R3和R4各自独立地为H或C1-C4烷基,或者R3和R4与它们所连接的氮原子一起形成I-吡咯烷基或哌啶基;Y为H、C1-C4烷基、C1-C4烷氧基或位于4、5、6或7位的CZ-C5烷氧基羰基;其中当R2位于2位时,R1位于3或4位,或者当R2位于7位时,R1位于3位。